Latest News & Features
Big Pharma
Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences. 4 February 2021
Genetics
Biotech company Illumina has won a dispute with Columbia University, after the Court of Appeals for the Federal Circuit backed an earlier ruling that the university’s DNA-sequencing patents were invalid. 2 February 2021
article
The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market. 1 February 2021
Americas
More than 250 million rapid COVID-19 tests will be made available for low and middle-income countries as part of a World Health Organization initiative to accelerate the global response to the virus. 1 February 2021
article
We hear from Oxford University Innovations and HGF about how collaboration has helped the faster development of the much needed vaccines in this past year. Hear from our panellists as they discuss the advantages of collaboration, how to pick a partner, and whether partnering up changes your normal practices. We will also hear about how to navigate the patenting of a new vaccine developed by a joint enterprise. 28 January 2021
Big Pharma
Biopharmaceutical company, Quercis Pharma, has exclusively licensed two patents to enhance its ability to provide approved treatments for COVID-19 and cancer. 28 January 2021
Americas
The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law. 28 January 2021
Americas
In a win for Johnson & Johnson, its Actelion unit has settled an infringement lawsuit after generic drug maker Laurus conceded that a patent for a pulmonary hypertension drug was valid. 28 January 2021
Big Pharma
The US Court of Appeals for the Federal Circuit has dismissed an attempt by Valeant Pharmaceuticals to overturn a ruling that restricted where Hatch-Waxman Act patent lawsuits can be filed. 27 January 2021
Big Pharma
Reckitt Benckiser has dropped a $1.4bn claim against former subsidiary Indivior, which it filed following its record settlement with the US government over the marketing of an opioid treatment. 26 January 2021